A new approach to reduce lung injury caused by inflammation
Deubiquitinating and inhibiting Hsp90 by USP40 mitigates lung injury
This study is looking at a new way to help people with acute lung injury, which can happen after pneumonia or sepsis, by targeting a protein that causes lung inflammation and damage, with the hope of finding better treatments for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10618145 on NIH RePORTER |
What this research studies
This research investigates a novel therapeutic strategy for acute lung injury (ALI), a serious condition often resulting from pneumonia or sepsis. The study focuses on the role of a protein called Hsp90, which contributes to inflammation and damage in the lungs. By using a specific enzyme, USP40, the researchers aim to inhibit Hsp90's activity, thereby reducing inflammation and preserving the integrity of blood vessel barriers in the lungs. The research will explore the molecular mechanisms involved in this process to develop effective treatments for patients suffering from ALI.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients experiencing acute lung injury due to pneumonia or sepsis.
Not a fit: Patients with chronic lung conditions or those not experiencing acute lung injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce mortality and improve recovery for patients with acute lung injury.
How similar studies have performed: Previous research has shown that inhibiting Hsp90 can reduce the severity of acute lung injury in animal models, indicating potential for success in this approach.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Zhao, Jing — Ohio State University
- Study coordinator: Zhao, Jing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.